CCMU
VKTX icon

Cheyne Capital Management (UK)’s Viking Therapeutics VKTX Stock Holding History

Cheyne Capital Management (UK)’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-64,753
Closed -$609K – 52
2022
Q4 		$609K Buy
+64,753
New +$289K 1.06% 32

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Cheyne Capital Management (UK)'s VKTX Position: Q1 2023 in Review

Cheyne Capital Management (UK) sold out of Viking Therapeutics (VKTX) in Q1 2023, closing a stake of 64,753 shares — an estimated $609K sold.

Cheyne Capital Management (UK) first reported a position in VKTX in Q4 2022 and held it in 1 quarter. The position peaked at $609K in Q4 2022. 184 funds tracked by Wall St. Rank hold VKTX as of Q1 2023.

  • Cheyne Capital Management (UK) reported no remaining Viking Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Cheyne Capital Management (UK) sold 64,753 Viking Therapeutics shares in Q1 2023, an estimated $609K.
  • Cheyne Capital Management (UK) first reported a position in Viking Therapeutics in Q4 2022 and held it in 1 quarter.
  • Cheyne Capital Management (UK)'s Viking Therapeutics position peaked at $609K in Q4 2022.
  • 184 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2023.

Based on Cheyne Capital Management (UK)'s 13F filing for Q1 2023, filed 3 May 2023.